Oncogene amplification and overexpression of oncoproteins in thyroid papillary cancer

In Vivo

Volumn 19, Issue 2, 2005, Pages 465-470

  Várkondi, Edit ^a   Gyory, Ferenc ^b   Nagy, András ^b   Kiss, István ^c   Ember, István ^c   Kozma, László ^d  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c UNIVERSITY OF PÉCS   (Hungary)

^d Reg Blood Transfusion Ctr Debrecen   (Hungary)

Author keywords

Cyclin D1; Estrogen receptor; Oncogenes; p53; Papillary cancer; Thyroid

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE; ESTROGEN RECEPTOR; MYC PROTEIN; ONCOPROTEIN; PROTEIN P21; PROTEIN P53; RAS PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CHROMOSOME ABERRATION; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; MALE; ONCOGENE C MYC; ONCOGENE H RAS; PHENOTYPE; PROGNOSIS; THYROID PAPILLARY CARCINOMA; TUMOR SUPPRESSOR GENE;

EID: 16344370219     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Ottó Sz and Kásler M: Rákmortalitás és -incidencia hazánkban, az európai adatok tükrében. Magyar Onkológia 46: 111-117, 2002.
2. Lukács GL, Szakáll Sz, Kozma L et al: Veränderungen der epidemiologischen Parameter von SD-Erkrankungen in Ostungarn zehn Jahre nach Tschernobyl in Langenbecks. Arch Chir Suppl II 1997, pp 375-377
3. Farid NR, Shi Y and Zou M: Molecular basis of thyroid cancer. Endocrine Rev 15(2): 202-232, 1994.
4. Soares P and Sobrinho-Simoes M: Recent advances in cytometry, cytogenetics and molecular genetics of thyroid tumours and tumour-like lesions. Path Res Pract 191: 304-317, 1995.
5. Yang Y: Expression, amplification and rearrangement of c-myc gene in human thyroid carcinoma. Chung Hua I Hsueh Tsa Chih Taipei 71(6): 304-306, 1991.
6. Romano MI, Grattone M, Karner MP et al: Relationship between the level of c-myc mRNA and histologic aggressiveness in thyroid tumors. Horm Res 39(3-4): 161-5, 1993.
7. Shahedian B, Shi Y, Zou M and Farid NR: Thyroid carcinoma is characterized by genomic instability: evidence from p53 mutations. Mol Genet Metab 72(2): 155-63, 2001.
8. Fagin JA, Matsuo K, Karmakar A et al: High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91(1): 179-184, 1993.
9. Dobashi Y, Sakamoto A, Sugimura H et al: Overexpression of p53 as a possible prognostic factor in human thyroid carcinoma. Am J Surg Pathol 17(4): 375-381, 1993.
10. Dobashi Y, Sugimura H, Sakamoto A et al: Stepwise participation of p53 gene mutation during differentiation of human thyroid carcinomas. Diagnostic Mol Pathol 3(1): 9-14, 1994.
11. Lazzereschi D, Sambuco L, Carnovale SC et al: Cyclin D1 and cyclin E expression in malignant thyroid cells and in human thyroid carcinomas. Int J Cancer 76(6): 806-811, 1998.
12. Muro CCA, Holt T, Klotch D et al: Cyclin D1 expression as a prognostic parameter in papillary carcinoma of the thyroid. Otolaryngol Head Neck Surg 120(2): 200-207, 1999.
13. Bernards R: CDK-independent activities of D type cyclins. Bioshimica et Biophysica Acta 1424: M17-M22, 1999.
14. Zwijsen RM, Wientjens E, Klompmaker R, van der Sman J, Bernards R and Michalides RJ: CDK-independent activation of estrogen receptor by cyclin D1. Cell 88(3): 405-15, 1997.
15. Gao X and Honn KV: Recessive oncogenes: current status. Pathol Oncol Res 1(1): 7-22, 1995.
16. Wang S, Wuu J, Savas L et al: The role of cell cycle regulatory protein, cyclin D1, cyclin E, and p27 in thyroid carcinogenesis. Hum Pathol 29(11): 1304-1309, 1998.
17. Spiessel, Beahrs, Hermanek et al: Pajzsmirigy. In TNM-atlasz (translation: Dr. Elek Farkas), ed. Springler Hungarica Kiadó Kft., Budapest 1992, pp 78-83.
18. Goelz SE, Hamilton SR and Vogelstein B: Purification of DNA from formaldehyde fixed and paraffin embedded human tissue. Biochem Biophys Res Commun 130: 118-126, 1985.
19. Nishikura K, Ar-Rushdi A, Erikson J et al: Differential expression of the normal and of the translocated human c-myc oncogenes in B cells. Proc Natl Acad Sci 80: 4822-4826, 1983.
20. Mc Coy Ms, Toole JJ, Cunningham JM, Chang EH, Lowy DR and Weinberg RA: Characterisation of a human colon/lung carcinoma oncogene. Nature 302: 79-81, 1983.
21. Masharani U, Wolf D and Fossard PM: Ban II and Sea I RFLP at the human p53 gene locus. Nucleic Acid Res 16: 7757-7761, 1988.
22. Hemmer S, Wasenius VM, Knuutila S et al: DNA copy number changes in thyroid carcinoma. Am J Pathol 154(5): 1539-1547, 1999.
23. Matsubayashi S, Kawai K, Matsumoto Y et al: The correlation between papillary thyroid carcinoma and lymphocytic infiltration in the thyroid gland. J Clin Endocrinol Metab 80(12): 3421-3424, 1995.
24. Ozaki O, Ito K, Mimura T, Sugino K and Hosoda Y: Papillary carcinoma of the thyroid. Tall-cell variant with extensive lymphocyte infiltration. Am J Surg Pathol 20(6): 695-698, 1996.
25. Basolo F, Caligo MA, Pinchera A et al: Cyclin D1 overexpression in thyroid carcinomas: relation with clinico-pathological parameters, retinoblastoma gene product, and Ki67 labeling index. Thyroid 10: 741-746, 2000.
26. Jones JM, Cui XS, Medina D et al: Heterozygosity of p21 WAF1/CIP1 enhances tumor cell proliferation and cyclin D1-associated kinase activity in a murine mammary cancer model. Cell Growth Differ 10(4): 213-222, 1999.
27. Van Holven KH, Menendez-Botet CJ, Strong EW and Huvos AG: Estrogen and progesterone receptor content in human thyroid disease. Am J Clin Pathol 99: 175-181, 1993.
28. Inoue H, Oshimo K, Miki H et al: Immunohistochemical study of estrogen receptors and the responsiveness to estrogen in papillary thyroid carcinoma. Cancer 72(4): 1364-1368, 1993.
29. Hiasa Y, Nishioka H, Kitahori Y et al: Immunohistochemical analysis of estrogen receptors in 313 paraffin section cases of human thyroid tissue. Oncology 50(2): 132-136, 1993.
30. Ho YS, Tseng SC, Chin TY et al: p53 gene mutation in thyroid carcinoma. Cancer Lett 103(1): 57-63, 1996.
31. Esik O, Szentirmai Z, Tursnady G et al: Malignus pajzsmirigy tumorok Magyarországon: morbiditás és mortalitás. Orv Hetil 137(17): 905-911, 1996.
32. Wyllie FS, Haughton MF, Rowson JM et al: Human thyroid cancer as a source of iso-genic, iso-phenotypic cell lines with or without functional p53. Br J Cancer 79(7-8): 1111-1120, 1999.
33. Ito Y, Kobayashi T, Takeda T et al: Expression of p21 (WAF1/CIP1) protein in clinical thyroid tissues. Br J Cancer 74(8): 1269-1274, 1996.
34. Puglisi F, Cesselli D, Damante G, Pellizzari L, Beltrami CA and Di Loreto C: Expression of Pax-8, p53 and bcl-2 in human benign and malignant thyroid diseases. Anticancer Res 20(1A): 311-6, 2000.